Fungus

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fungus

What is Fungus? (Fluconazole)

Property Description
Active ingredient Fluconazole
Form Tablet, Capsule, Oral Suspension, Intravenous Solution
Pharmacological class Systemic Antifungal Agent, Triazole Derivative
Common use Addressing Fungal Infections (Mycoses)
Origin Synthetic Compound

What Type of Medicine is Fungus?

The medicine known commercially as Fungus is a prescription-only medicine (Rx) defined by its active compound, Fluconazole. It is a synthetic compound classified as a Systemic antifungal agent, designed to work throughout the body rather than just on the skin’s surface. Fluconazole is a member of the azole class of antifungals.


Specifically, Fluconazole is a Triazole derivative within the larger Azole antifungal class. This classification is based on its core chemical structure. Unlike older, less specific antifungals, Fluconazole's chemical profile is clinically recognized for its high bioavailability, making it suitable for treating complex systemic fungal infections, where the active agent must be readily absorbed into the bloodstream.

Composition and Available Preparations

The active component in Fungus is Fluconazole, and it is manufactured in multiple dosage forms to accommodate various patient needs and routes of administration. These preparations include the tablet and capsule for the oral route, as well as an oral suspension and an intravenous solution for administration by infusion.


The availability of both oral and intravenous solution forms is a key distinguishing feature of the Fluconazole formulation. This dual availability ensures that the medicine can be delivered effectively, whether through convenient oral dosing for maintenance therapy, or via rapid, guaranteed intravenous delivery for treating acute, life-threatening systemic mycoses requiring immediate clinical intervention.

What is the General Purpose of This Antifungal Agent?

The overall purpose of this medicine, as an Antifungal agent, is to address the underlying cause of various fungal infections and mycoses. Its primary function is to combat the fungal pathogens responsible for the infection by disrupting their fundamental cellular processes.


Fluconazole achieves its therapeutic effect primarily as a fungistatic agent, meaning it works to prevent the fungal organism from growing and reproducing, thereby controlling the spread of the infection. This action is rooted in the targeted impairment of ergosterol synthesis, a process vital for maintaining the structural integrity of the fungal cell membrane, resulting in the drug's general benefit of clearing or controlling systemic mycoses.

What side effects are possible with Fungus?

Possible Side Effects and Safety Information

The official safety profile for Fluconazole (Fungus) organizes potential adverse reactions by both frequency and the physiological system affected, strictly following government regulatory standards. These safety classifications define the documented risk profile of the systemic antifungal agent.


Frequency-Classified Adverse Reactions

The majority of documented adverse events fall into the Common and Uncommon categories. Common reactions (occurring in 1% to 10% of patients) typically involve the gastrointestinal system (e.g., nausea, abdominal pain, diarrhea) and the nervous system (headache), along with increases in certain liver enzymes. Uncommon reactions include anemia, insomnia, seizures, dizziness, pruritus (itching), and fatigue.


System-Organ-Class Groupings and Serious Reactions

Adverse effects are formally grouped into System Organ Classes (SOC) in regulatory documents, including Hepatobiliary Disorders, Skin and Subcutaneous Tissue Disorders, and Cardiac Disorders.

Of critical importance are Rare but serious adverse reactions (occurring in less than 0.1% of patients), which include severe hepatotoxicity (such as hepatic failure or hepatocellular necrosis), serious skin conditions like Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), and the potential for severe ventricular arrhythmias, specifically QT prolongation and Torsade de pointes.


Population-Specific Safety Notes

The label specifies that caution is required in patients with pre-existing hepatic dysfunction due to the drug's potential for severe liver toxicity. Furthermore, the pharmacokinetics of the drug are markedly affected by reduced renal function, necessitating regulatory consideration for patients with kidney impairment. Use is explicitly restricted or contraindicated when co-administered with certain drugs known to prolong the QT interval and are metabolized via the CYP3A4 enzyme, due to the risk of serious cardiac events.

Overdose and Emergency Response

Overdose and when to seek help

The following information is based strictly on the regulatory descriptions of overdosage for Fluconazole, detailing the documented clinical manifestations and the required emergency actions.

Element Official Regulatory Description
Documented Manifestations Reports of hallucination and paranoid behavior have been documented in association with acute overdosage.
Severe Outcomes Overexposure carries a risk of cardiotoxicity, including QT interval prolongation and Torsades de pointes (TdP). This includes the potential for life-threatening ventricular arrhythmias.
Urgent Action Required Seek immediate medical attention or contact a Poison Control Center for known or suspected overdosage.

Official Regulatory Management

When overdosage occurs, no specific antidote is known. Therefore, regulatory guidance mandates that management must be focused on supportive care and reducing the drug concentration. Treatment consists of symptomatic treatment with supportive measures. Gastric lavage may be considered if medically necessary. High plasma levels of Fluconazole can be effectively reduced using hemodialysis, with a single three-hour session documented to decrease plasma concentrations by approximately 50%. A population-specific consideration notes that patients with pre-existing conditions such as hypokalemia or advanced cardiac failure are documented to have an increased risk of the most severe cardiac effects.

Therapeutic Uses of Fungus

What Fungus Treats: Main Uses and Benefits

The therapeutic uses generally cover conditions presenting with systemic or localized discomfort caused by fungal pathogens. The therapeutic domain includes serious systemic fungal conditions like candidemia and cryptococcal meningitis, as well as infections of the mucous membranes such as oral thrush, esophageal candidiasis, and vaginal yeast infections.

The medication is relevant in clinical settings involving both acute symptomatic episodes and recurrent or episodic manifestations of these conditions, helping to address symptoms related to inflammatory or irritative states. In high-risk patient groups (e.g., those undergoing chemotherapy or managing HIV/AIDS), the drug is commonly used to help manage the risk of new or repeated serious fungal episodes, assisting with maintaining functional stability.

“The medication is applied across therapeutic domains where additional symptomatic support is needed, which contributes to improved comfort during periods of heightened symptoms.”


Quick Fact: Symptomatic Support
Symptom Clusters Relevant for Management: Soreness, irritation, intense itching, and painful swallowing associated with fungal manifestations.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility to use Fungus (Fluconazole) is strictly defined by regulatory authorities and focuses on patient history and physiological status.

Contraindications

The medicine is formally contraindicated for patients with a known history of hypersensitivity to fluconazole itself or to other substances within the azole antifungal class.

Restricted and Conditional Use

Eligibility is restricted for individuals with pre-existing conditions. Official labeling specifies that caution is required for patients with severe renal impairment or hepatic impairment, as these conditions necessitate conditional use and specialized monitoring. Use is also restricted in patients who have cardiac risk factors for QTc interval prolongation or uncorrected electrolyte disturbances such as hypokalemia.

Age and Life Stage

The medicine is approved for adults and for specific uses in pediatric patients (typically 6 months and older). Use in neonates and infants is highly restricted and requires specialized protocols. Furthermore, use is generally not recommended during pregnancy or by lactating patients, due to risk considerations formally documented in prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Fungus has a high potential for clinically significant drug interactions, primarily due to its role as a strong inhibitor of the Cytochrome P450 3A4 (CYP3A4) enzyme and an inhibitor of CYP2D6. This action increases the plasma concentrations of many co-administered medicines, which can lead to serious adverse effects.

Contraindicated Combinations

Official regulatory documents state that co-administration is contraindicated with numerous CYP3A4-metabolized drugs, including certain HMG-CoA reductase inhibitors (statins like simvastatin and lovastatin) and specific antiarrhythmics (such as dofetilide and quinidine). These combinations are prohibited because the resultant high drug levels may cause QT prolongation and life-threatening ventricular arrhythmias.

Other Clinically Significant Interactions

  • CYP3A4 Inducers: Co-administration with strong CYP3A4 inducers (e.g., rifampin, phenytoin) is contraindicated as they decrease the plasma concentration of Fungus, potentially leading to treatment failure.
  • Acid-Reducing Agents: The drug's absorption is dependent on gastric acidity. Products that raise stomach pH, such as Proton Pump Inhibitors (PPIs) and H2-receptor antagonists, can significantly reduce Fungus plasma levels. Administration of these agents may need to be strictly timed or avoided.
  • CYP2D6 Substrates: Increased exposure to drugs metabolized by CYP2D6 (e.g., certain antidepressants or antipsychotics) may necessitate dose reduction of the co-administered drug or careful patient monitoring.

Mechanism of Action

Fluconazole's mechanism involves inhibiting the synthesis pathway required for fungal cell membrane sterols. This action results in a purely fungistatic effect at relevant concentrations, achieved through molecular-level enzyme inhibition.

Targeted Inhibition of Fungal CYP51 Enzyme

Fluconazole exerts its precise molecular action through the reversible inhibition of the fungal enzyme lanosterol 14alpha-demethylase ( CYP51). This interaction blocks an early step in the fungal metabolic process required for converting lanosterol into the essential membrane component, ergosterol.

Cascade of Ergosterol Depletion and Structural Compromise

Enzyme blockade initiates a cascade resulting in the depletion of ergosterol, a sterol necessary for maintaining membrane fluidity and function. Concurrently, the accumulation of toxic precursor sterols (like lanosterol) further destabilizes the cell. This results in compromised structural integrity and the physiological consequence of inhibited fungal proliferation, which controls the pathogen load at a cellular level.

Dosage and Administration Information

How Fungus (Fluconazole) is Used in Clinical Practice

Fungus is administered according to standardized regimens established in official regulatory documents, defining the route, dose, frequency, and duration of use. The medicine is available for administration via two officially approved routes: the oral route (as tablets, capsules, or suspension) and the intravenous (IV) route (as a solution for infusion).

Dosing and Administration Schedules

Administration typically begins with a loading dose on Day 1, which is often double the maintenance dose, to rapidly achieve the required systemic concentration. The maintenance dose subsequently falls within a range of 50 mg to 800 mg once daily, adjusted based on the specific clinical scenario. The standard dosing frequency for most conditions is once daily, although a single 150 mg oral dose is specified for acute cases, and once-weekly schedules are used for certain recurrent conditions.

Oral forms may be administered with or without food. For the IV route, the solution must be administered via infusion at a rate not exceeding 10 mL/minute.

Duration and Population-Specific Rules

Treatment duration varies significantly: from a single dose or short-term courses (measured in weeks) for localized mucosal infections, to prolonged maintenance plans (measured in months or years) for preventing relapse in high-risk patients. Regulatory guidance mandates specific dose modification for certain populations. For instance, the multi-dose regimen must be reduced by 50% for individuals with moderate to severe renal impairment (creatinine clearance le 50 mL/min). Pediatric dosing is calculated using a mg/kg basis.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fungus

Evidence for Studies of Invasive Candidiasis (Bloodstream and Systemic Infections)

Research examining Fluconazole was conducted using Randomized Controlled Trials (RCTs) and systematic reviews, primarily focusing on systemic fungal infections, such as those occurring in the bloodstream (candidemia). These studies were applied in populations of non-critically ill adults, clinically stable patients, and high-risk neonates. The evidence indicates that for patients with susceptible strains of Candida, studies reported patterns related to mycological clearance (fungus no longer detectable) when Fluconazole was evaluated as a primary therapy or for the continuation of therapy following initial stabilization. Studies describe that certain fungal species, notably Candida glabrata, have been documented as exhibiting variable or reduced susceptibility.


Evidence for Studies of Mucosal (Oral and Esophageal) Candidiasis

The evidence base for infections of the mucous membranes, such as oral thrush, includes numerous short-term RCTs. These trials were designed to assess measures of clinical cure (resolution of physical discomfort) and mycological eradication. Study populations have included both healthy adults and those who are immunocompromised, particularly individuals with HIV infection, who are studied for recurrent infections. Research describes changes measured during the study period, and studies reported measurements of both clinical and laboratory clearance in susceptible infections following short courses of treatment.


Research Gaps and Areas of Uncertainty

A fundamental research gap lies in the increasing documentation of fungal species that have been described as having a reduced susceptibility to Fluconazole. Additionally, many initial trials were conducted with modest sample sizes or had limited follow-up durations. There is also limited information regarding long-term outcomes in several key indications, and the research does not determine whether an individual will respond similarly to the group patterns observed in the studies.

Key Studies & References

  1. NIH MedlinePlus Drug Information - Fluconazole Uses and General Classification

Frequently Asked Questions (FAQ)

Common questions about Fungus (FAQ)

Q: Is Fungus the same kind of medicine as other treatments for this condition?

A: Official documents classify Fungus (Fluconazole) as a systemic antifungal agent. It is specifically defined as a triazole derivative, which is a type of azole antifungal medicine. This classification helps describe how the medicine works throughout the body to address fungal infections.


Q: How quickly does Fungus start working after you take it?

A: According to the official product information, the time it takes for the drug to reach its highest concentration in the bloodstream (known as peak plasma concentration) is generally described as occurring between 1 and 2 hours after taking an oral dose. This refers to how quickly the medicine enters the system, which is the start of its pharmacological action.


Q: Can Fungus cause allergic reactions, and what are the signs?

A: Official labeling notes the potential for severe allergic reactions, including hypersensitivity and anaphylaxis. The documented signs for these serious events can include a severe rash or itching, swelling of the face, lips, or throat, and experiencing breathing problems. A known history of hypersensitivity to the medicine is listed as a contraindication.


Q: Why do some people experience fatigue when using Fungus?

A: Official safety information lists fatigue as an uncommon documented adverse reaction that has been reported by patients using this medicine. While the underlying mechanism is not detailed in patient materials, this effect is recognized and cataloged by regulatory bodies.


Q: Are there known issues with driving or operating machinery while taking Fungus?

A: Official documents describe that, due to the occasional occurrence of side effects like dizziness or seizures, patients are cautioned regarding activities such as driving vehicles or operating machines.


Q: Can children or teenagers use Fungus?

A: Official regulatory documents define specific dosing and protocols for the pediatric population, depending on the specific condition being treated. This includes term newborn infants, infants, toddlers, children, and adolescents up to 17 years old.


Q: Is Fungus appropriate for older adults (seniors)?

A: Official labeling includes a specific section on Geriatric Use. Regulatory documents indicate that pharmacokinetic data has been reviewed for subjects 65 years of age or older.


Q: Does the use of Fungus require any special monitoring or blood tests?

A: Official information advises caution and specifies that monitoring may be required for patients with pre-existing conditions, particularly hepatic (liver) or renal (kidney) dysfunction. This is because the drug can potentially affect these organs.


Q: What are the official guidelines regarding long-term use of Fungus?

A: The official prescribing information defines prolonged maintenance plans for certain high-risk patients to prevent relapse. For these specific uses, treatment duration can be measured in months or years. The duration is typically determined by the clinical scenario.


Q: Does Fungus affect birth control pills?

A: Official regulatory documents indicate that co-administration of Fungus can result in increased systemic exposure (higher concentration) of the active components of some oral contraceptives. This potential interaction is noted in the prescribing information.


Q: What is the general success rate mentioned in the research for Fungus?

A: The evidence base for Fungus (Fluconazole) is described in terms of specific, measurable outcomes. These measurements include mycological clearance (meaning the fungus is no longer detectable) and clinical cure (meaning the physical discomfort or signs of the infection have resolved).


Q: Does Fungus interact with caffeine?

A: Scientific reviews indicate that Fungus may slow down the body’s clearance of caffeine. This effect is based on the way the drug interacts with certain liver enzymes, and it could potentially lead to an increased risk of side effects associated with caffeine.


Q: Are there any known interactions between Fungus and anxiety medications?

A: Official labeling and medical information cite potential interactions with certain drugs, including some used to treat anxiety disorders (e.g., specific antidepressants). Because of this, patient monitoring may be required when these medicines are co-administered.


Q: What if I take too much Fungus by accident?

A: The official prescribing information includes a specific section detailing OVERDOSAGE. This section describes the appropriate clinical response that is typically followed for such an event.


Q: How does Fungus affect the immune system?

A: The primary function of Fungus is to combat fungal pathogens directly by acting as a fungistatic agent, which means it prevents the fungal organism from growing and reproducing. Its mechanism of action is focused on the fungus, not a direct function on the body's native immune system.


Q: Why might Fungus be prescribed over topical options for the same condition?

A: Official documents describe Fungus (Fluconazole) as a systemic antifungal agent intended to work throughout the body. This makes it appropriate for addressing systemic infections and mycoses that require internal action, in contrast to treatments that only work on the skin's surface.


Q: How long do you need to take Fungus generally?

A: Official guidance indicates treatment duration varies significantly depending on the infection type. Treatment can range from a single dose or short-term courses (measured in weeks) for localized infections, up to prolonged maintenance plans (measured in months or years) for preventing relapse in high-risk patients.


Q: Are there any common reasons why someone might stop taking Fungus?

A: Reasons for stopping treatment, as defined in regulatory documents, include a known history of hypersensitivity to the medicine or the occurrence of rare but serious adverse reactions. These serious reactions include severe hepatic toxicity (liver damage) or serious skin conditions.


Q: Can I take Fungus if I am already taking vitamins or herbal supplements?

A: Official warnings highlight the drug's role as an inhibitor of certain liver enzymes (CYP2C9, CYP3A4, CYP2C19). This enzyme activity can affect the concentration of many co-administered medicines, including those metabolized by these pathways. The risk is present for co-administered medicines and supplements that use these same metabolic pathways.


Q: Are there specific foods or drinks that should be avoided when using Fungus?

A: Official prescribing information states that the oral forms of the medicine may be taken with or without food. There are no specific foods or drinks listed in regulatory documents that are known to affect the absorption of Fungus.


Q: Is it okay to drink alcohol while using Fungus?

A: Official documents do not generally describe a direct drug-alcohol interaction. However, regulatory warnings note that side effects like dizziness and headache may be worsened by alcohol consumption. Additionally, serious hepatotoxicity (liver damage) is a known rare risk associated with Fungus.


Q: Why might a patient be considered ineligible to use Fungus?

A: Official documents list absolute contraindications. These include a known history of hypersensitivity to the medicine or azole class, and the co-administration of specific other medicines that may cause serious heart rhythm changes when combined with Fungus.

How should Fungus be stored and disposed of?

How to Store and Dispose of Fluconazole

Fluconazole must be stored according to regulatory specifications to maintain its stability. Tablets and capsules require storage at Controlled Room Temperature, typically 25 C (77 F), with excursions permitted up to 30 C. All forms must be stored out of the sight and reach of children and protected from moisture.

Preparation Storage Requirement
Oral Suspension (Mixed) Stable for 14 days; Do not freeze and discard unused portion after 14 days.

Disposal must follow local regulatory guidelines. Unused or expired medication should not be disposed of in wastewater or general household waste; instead, use a medicine take-back program if available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fungus found in:

A-Z Index: